John L Lamattina - Net Worth and Insider Trading
John L Lamattina Net Worth
The estimated net worth of John L Lamattina is at least $13 Million dollars as of 2024-04-28. John L Lamattina is the Senior Vice President of Pfizer Inc and owns about 429,454 shares of Pfizer Inc (PFE) stock worth over $11 Million. John L Lamattina is the Director of Ligand Pharmaceuticals Inc and owns about 25,398 shares of Ligand Pharmaceuticals Inc (LGND) stock worth over $2 Million. John L Lamattina is also the Director of Immunome Inc and owns about 51,828 shares of Immunome Inc (IMNM) stock worth over $711,598. Details can be seen in John L Lamattina's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that John L Lamattina has not made any transactions after 2021-11-16 and currently still holds the listed stock(s).
Transaction Summary of John L Lamattina
John L Lamattina Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, John L Lamattina owns 5 companies in total, including Immunome Inc (IMNM) , Ligand Pharmaceuticals Inc (LGND) , and Larimar Therapeutics Inc (LRMR) among others .
Click here to see the complete history of John L Lamattina’s form 4 insider trades.
Insider Ownership Summary of John L Lamattina
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| IMNM | Immunome Inc | 2021-05-24 | director |
| LGND | Ligand Pharmaceuticals Inc | 2021-11-16 | director |
| LRMR | Larimar Therapeutics Inc | 2015-07-13 | director |
| PFE | Pfizer Inc | 2007-06-15 | Senior Vice President |
| TMO | Thermo Fisher Scientific Inc | 2004-03-09 | director |
John L Lamattina Latest Holdings Summary
John L Lamattina currently owns a total of 3 stocks. Among these stocks, John L Lamattina owns 429,454 shares of Pfizer Inc (PFE) as of June 15, 2007, with a value of $11 Million and a weighting of 81.33%. John L Lamattina owns 25,398 shares of Ligand Pharmaceuticals Inc (LGND) as of November 16, 2021, with a value of $2 Million and a weighting of 13.36%. John L Lamattina also owns 51,828 shares of Immunome Inc (IMNM) as of May 24, 2021, with a value of $711,598 and a weighting of 5.31%.
Latest Holdings of John L Lamattina
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| PFE | Pfizer Inc | 2007-06-15 | 429,454 | 25.40 | 10,908,132 |
| LGND | Ligand Pharmaceuticals Inc | 2021-11-16 | 25,398 | 70.57 | 1,792,337 |
| IMNM | Immunome Inc | 2021-05-24 | 51,828 | 13.73 | 711,598 |
Holding Weightings of John L Lamattina
John L Lamattina Form 4 Trading Tracker
According to the SEC Form 4 filings, John L Lamattina has made a total of 0 transactions in Pfizer Inc (PFE) over the past 5 years. The most-recent trade in Pfizer Inc is the sale of 36,066 shares on June 15, 2007, which brought John L Lamattina around $955,028.
According to the SEC Form 4 filings, John L Lamattina has made a total of 1 transactions in Ligand Pharmaceuticals Inc (LGND) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Ligand Pharmaceuticals Inc is the sale of 4,835 shares on November 16, 2021, which brought John L Lamattina around $782,593.
According to the SEC Form 4 filings, John L Lamattina has made a total of 1 transactions in Immunome Inc (IMNM) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Immunome Inc is the acquisition of 5,440 shares on May 24, 2021, which cost John L Lamattina around $101,021.
Insider Trading History of John L Lamattina
- 1
John L Lamattina Trading Performance
GuruFocus tracks the stock performance after each of John L Lamattina's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John L Lamattina is -12.09%. GuruFocus also compares John L Lamattina's trading performance to market benchmark return within the same time period. The performance of stocks bought by John L Lamattina within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how John L Lamattina's insider trading performs compared to the benchmark.
Performance of John L Lamattina
Average Return
-10.55%
Outperforming Transactions
50%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -4.49 | -12.09 | 19.01 | -10.55 | 3.7 | 92.76 |
| Relative Return to S&P 500(%) | -6.09 | -14.26 | 18.75 | -10.06 | -0.42 | 80.06 |
John L Lamattina Ownership Network
Ownership Network List of John L Lamattina
Ownership Network Relation of John L Lamattina
John L Lamattina Owned Company Details
What does Immunome Inc do?
Who are the key executives at Immunome Inc?
John L Lamattina is the director of Immunome Inc. Other key executives at Immunome Inc include Chief Medical Officer Robert Lechleider , director & President and CEO Clay B Siegall , and director & other: See remarks Isaac Barchas .
Immunome Inc (IMNM) Insider Trades Summary
Over the past 18 months, John L Lamattina made no insider transaction in Immunome Inc (IMNM). Other recent insider transactions involving Immunome Inc (IMNM) include a net purchase of 169,204 shares made by Clay B Siegall , and a net purchase of 42,300 shares made by Bruce Turner .
In summary, during the past 3 months, insiders sold 0 shares of Immunome Inc (IMNM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Immunome Inc (IMNM) were sold and 211,504 shares were bought by its insiders, resulting in a net purchase of 211,504 shares.
Immunome Inc (IMNM)'s detailed insider trading history can be found in Insider Trading Tracker table.
Immunome Inc Insider Transactions
John L Lamattina Mailing Address
Above is the net worth, insider trading, and ownership report for John L Lamattina. You might contact John L Lamattina via mailing address: 81 Wyman St, Post Office Box 9046, Waltham Ma 02454.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
